Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Seco...(ct anticipate estimate plan inte...),Health

Date:11/19/2008

ct," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words. Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable. We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning consistent growth in our net sales and income in the coming years, improving the efficacy of VNS Therapy(TM) for epilepsy, successfully developing a product capable of seizure detection and improving efficacy with new stimulation parameters, obtaining regulatory approvals in Japan, achievement of consistent unit growth of 10% to 20%, an operating margin of 25% by fiscal 2011, sustained increases in shareholder value, fiscal 2009 sales of $136 million to $140 million, and positive income in fiscal 2009. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy(TM) and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy(TM) for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's est
'/>"/>

SOURCE Cyberonics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine news :

1. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
2. Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS
3. Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike
4. Cyberonics to Present at UBS Global Life Sciences Conference
5. Cyberonics to Present at Canaccord Adams 28th Annual Global Growth Conference
6. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 First Quarter Financial Results
7. Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference
8. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2008 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
11. Cyberonics Licenses Obesity-Related Patents